Multiple class action cases have been filed against Tempus AI alleging that, during its acquisition of Ambry Genetics, the company improperly collected and disclosed genetic information without obtaining prior written consent from individuals during its acquisition of Ambry. Tempus acquired Ambry, a genetic testing firm, in February 2025 for $600 million. The acquisition included the
genetic information
Getting Too Personal? Illinois Court Says Family Medical History is Genetic Information
By Roma Patel on
Posted in Enforcement + Litigation
On May 15, 2025, a district court in Illinois denied a motion by defendant Hospital Sisters Health System and Saint Francis (HSHS) to dismiss a class action claim brought against the hospital system under the Illinois Genetic Information Privacy Act (GIPA).
GIPA regulates the use, disclosure, and acquisition of genetic information and has adopted the…
23andMe Confirms Threat Actors Accessed Accounts Without Authorization
By Linn Foster Freedman on
Posted in Data Privacy
We have published blog posts before on sharing genetic information and the risk associated with the disclosure of such sensitive information.
Unfortunately, our concerns have been realized. On Monday, October 9, 2023, 23andMe confirmed that its investigation into a data security incident involving customer profile information shared through its DNA Relatives feature “was compiled from…